Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

16 Sep 2005 13:06

ReNeuron Group plc16 September 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PERSONS DISCHARGINGMANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transactionrelating to the shares or debentures of the issuer should complete boxes 1 to16, 23 and 24. (2) An issuer making a notification in respect of a derivative relatingto the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23and 24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financialinstrument relating to the shares of the issuer (other than a debenture) shouldcomplete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or RENEURON GROUP PLC (ii) DR3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (ii) 3. Name of person discharging managerial 4. State whether notification relates to a person responsibilities/director connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person JOHN SINDEN MICHAEL HUNT 5. Indicate whether the notification is in 6. Description of shares (including class), respect of a holding of the person referred debentures or derivatives or financial to in 3 or 4 above or in respect of a instruments relating to shares non-beneficial interest3 7. Name of registered shareholders(s) and, if 8. State the nature of the transaction more than one, the number of shares held by each of them 9. Number of shares, debentures or financial 10. Percentage of issued class acquired (treasury instruments relating to shares acquired shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial 12. Percentage of issued class disposed (treasury instruments relating to shares disposed shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and 16. Date issuer informed of transaction total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised ANY TIME DURING THE PERIOD ENDING 23 JULY 2014 6 SEPTEMBER 2005 19. Total amount paid (if any) for grant of the 20. Description of shares or debentures involved option (class and number) JOHN SINDEN 650,000 ORDINARY SHARES NIL MICHAEL HUNT 900,000 ORDINARY SHARES 21. Exercise price (if fixed at time of grant) 22. Total number of shares or debentures over or indication that price is to be fixed at the time which options held following notification of exercise £0.10 PER SHARE JOHN SINDEN 1,955,260 OPTIONS AND WARRANTS MICHAEL HUNT 1,929,500 OPTIONS AND WARRANTS 23. Any additional information 24. Name of contact and telephone number for queries TIM MICKLEY, COLLINS STEWART 020 7523 8000 REPLACEMENT OPTIONS GRANTED UNDER THE COMPANY'S NEW SHARE OPTION SCHEME MICHAEL HUNT RENEURON 01483 302 560 Name and signature of duly authorised officer of issuer responsible for making notification MICHAEL HUNT CHIEF EXECUTIVE OFFICER-______________________________________ Date of notification 16/9/05 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Apr 20197:00 amRNSReNeuron to present at UK investor conference
4th Apr 20197:00 amRNSClinical update and conference presentation
28th Mar 20192:05 pmRNSSecond Price Monitoring Extn
28th Mar 20192:00 pmRNSPrice Monitoring Extension
18th Mar 201912:00 pmRNSAlliance for Regenerative Medicine presentation
18th Mar 20197:00 amRNSRetinal clinical trial progresses to next stage
12th Mar 20192:30 pmRNSNotification of Major Holdings
5th Mar 201912:56 pmRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
28th Feb 20197:00 amRNSBlock Listing Review and Total Voting Rights
20th Feb 20197:00 amRNSPositive preliminary data in US retinal trial
31st Jan 20197:00 amRNSNew exosome production scale-up data presented
24th Jan 20197:00 amRNSFirst patient treated in US stroke trial
4th Jan 20197:00 amRNSReNeuron signs exosome collaboration
14th Dec 20187:00 amRNSInterim Results
20th Nov 20182:00 pmRNSNotification of Interim Results
18th Oct 20187:00 amRNSReNeuron's lead cell line shows further potential
28th Sep 20182:16 pmRNSDirector/PDMR Interest in Shares and Share Options
27th Sep 20183:02 pmRNSDirectors Share Purchases
19th Sep 20184:40 pmRNSSecond Price Monitoring Extn
19th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness development update
12th Sep 201811:40 amRNSResult of AGM
12th Sep 20187:00 amRNSAGM Trading Update
31st Aug 20187:00 amRNSBlock Listing Review and TVR
31st Jul 20183:25 pmRNSPosting of Annual Report & Notice of AGM
17th Jul 20187:00 amRNSNotification of Major Holdings
16th Jul 20183:39 pmRNSNotification of Major Holdings
16th Jul 20187:00 amRNSNotification of Major Holdings
13th Jul 201811:50 amRNSNotification of Major Holdings
12th Jul 20187:00 amRNSPreliminary Results
11th Jul 20187:00 amRNSSigns retinal stem cell exclusivity agreement
4th Jul 20182:15 pmRNSNotification of Preliminary Results
17th May 20187:00 amRNSCapital Markets Event
4th May 20187:00 amRNSExosome data presented at ISCT conference
30th Apr 20187:00 amRNSCapital Markets Event and Webcast
19th Apr 20187:00 amRNSWins grant for retinal cell therapy development
10th Apr 20181:00 pmRNSAppointment of US-based Chief Medical Officer
26th Mar 20187:00 amRNSProduct Development Update
1st Mar 20187:00 amRNSBlock Listing Review and TVR
16th Feb 20187:00 amRNSBlock Listing Application
13th Feb 201810:00 amRNSPositive pre-clinical data in nerve injury
26th Jan 20187:00 amRNSPhase II stroke data presented at AHA conference
23rd Jan 201811:06 amRNSApproval of Share Capital Reorganisation
11th Jan 20187:00 amRNSFurther re Share Capital Reorganisation
5th Jan 20187:00 amRNSProposed Share Capital Reorganisation
14th Dec 20177:00 amRNSInterim results
14th Dec 20177:00 amRNSStroke clinical trial regulatory approval in US
8th Dec 20177:00 amRNSReNeuron opens US office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.